vicept - n. from Latin vita- life; and receptus (recipere) - to take back
A privately held specialty biopharmaceutical start-up focused on creating products for use in the largest and fastest growing sectors of the dermatology market.
Company founded with the mission to develop the first effective topically-applied treatment for the erythema (skin redness) associated with rosacea.
Innovator in the development of (
)-adrenergic receptor technology pursuing indications which include the treatment and prevention of Rosacea, Actinic (Solar) Purpura and peri-procedural bruising of the skin.
Recent News
July 19, 2011
Allergan, Inc. to acquire privately held dermatologic company, Vicept Therapeutics.
April 19, 2011
Vicept Therapeutics Announces Positive Results from a Second Phase II Study of V-101 for the
Treatment of Type I Rosacea.
February 14, 2011
Vicept Therapeutics Secures $2.5M in Venture Debt Financing.
